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Background and objective: Cancer is a life-threatening disease worldwide and current
standard therapy cannot fulfill all clinical needs. Chinese herbal injections have been widely
used for cancer in Chinese and Western hospitals in China. This study aimed to apply
evidence mapping in order to provide an overview of the clinical application of Chinese
herbal injections in cancer care based on randomized controlled trials, systematic reviews,
and meta-analyses.
Methods and results: Seven databases were systematically searched for eligible
randomized controlled trials, systematic reviews, and meta-analyses for ten Chinese herbal
injections used in cancer treatment and covered in the Chinese national essential health
insurance program. Excel 2016 and RStudio were used to integrate and process the data.
In total 366 randomized controlled trials and 48 systematic reviews and meta-analyses
were included in the evidence mapping of herbal medicines including; Compound Kushen,
Shenqi Fuzheng, Aidi, Kangai, Kanglaite, Xiaoaiping, Cinobufacin, Brucea javanica oil
emulsion, Polyporus polysaccharide injection, and Astragalus polysaccharide for injection.
Health insurance restricts the scope of clinical application for these herbal injections. The
numbers of studies published increased, especially around 2013–2015. The most studied
cancer types were lung cancer (118, 32.2%), colorectal cancer (39, 10.7%), and gastric
cancer (39, 10.7%), and the most used injections were Compound Kushen (78, 21.3%),
Shenqi Fuzheng (76, 20.8%), and Aidi (63, 17.2%). The most consistently reported
benefits were observed for Compound Kushen, Shenqi Fuzheng, Aidi, and Kangai for
tumor response, quality of life, myelosuppression, and enhancing immunity.
Conclusion: The current evidence mapping provides an overview of the outcomes and
effects of Chinese herbal injections used in cancer care, and offers information on their
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clinical application which warrants further evidence-based research in order to inform
clinical and policy decision-making.
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INTRODUCTION
Cancer is one of the most common diseases worldwide. The global
cancer burden was estimated to have risen to 19.3 million new
cases with 10.0 million deaths in 2020 (The International Agency
for Research on Cancer (IARC), 2020). Currently, western anti-
cancer medications are the dominant treatment approach, but they
cannot meet all clinical needs in cancer care. As statistics show,
complementary and alternative therapies fulfill a great demand in
cancer treatment (Horneber et al., 2012), and the evidence-based
clinical practice of these therapies for cancer is growing and being
recommended (Greenlee et al., 2017).
In the field of traditional Chinese medicine (TCM), herbal
injections were developed in the 1940s and became an important
component of Chinese patent herbal drugs (Li et al., 2018), and
widely used in both Chinese medicine and Western medicine
hospitals in China. By 2015, the Chinese herbal injection
industry had reached 87.706 billion RMB (Rui Zheng et al.,
2018). However, with the strengthening of the reform of public
hospitals, the government has introduced a series of policies on the
use of adjuvant drugs and are dynamically adjusting the healthcare
insurance catalogue (National Health Commission, 2018; General
Office of the National Health Commission, Office of the National
Administration of Traditional Chinese Medicine, 2019). Given the
advent of strict regulations, the market share of Chinese herbal
injection declined rapidly. Evidence-based research is urgently
needed to support the rational and valuable use of Chinese
herbal injections in clinical practice.
An increasing number of randomized clinical trials (RCTs),
systematic reviews (SRs), and meta-analyses on Chinese herbal
injections for cancer care have been published in recent decades.
However, a large quantity of the clinical studies have used
inappropriate evidence synthesis, and a wide range of
conclusions on the different injections has made consensus on
the clinical utility of injections ambiguous. Evidence mapping is a
systematic search of a broad field which enables a comprehensive
analysis of the topic and can identify priority areas for future
research (Miake-Lye et al., 2016).
This study aimed to map the existing evidence from RCTs,
systematic reviews, and meta-analyses for ten Chinese herbal
injections which are categorized for use in cancer care in the
national basic medical insurance program in China, and to
provide precise indications for the clinical use of these injections.
METHODS
Inclusion Criteria
All RCTs, SRs, andmeta-analyses (except networkmeta-analyses) on
Chinese herbal injections for cancer care were included. The Chinese
herbal injections included were as follows: Compound Kushen,
Shenqi Fuzheng, Aidi, Kangai, Kanglaite, Xiaoaiping, Cinobufacin,
Brucea javanica oil emulsion, Polyporus polysaccharide injection and
Astragalus polysaccharide for injection. The included RCTs had to
state the inclusion criteria of the participants and appropriate
randomization methods as this would lead to a low risk of bias in
the random sequence generation assessment (Higgins et al., 2011).
Based on part of the critical domains in AMSTAR2 (AMeaSurement
Tool to Assess systematic Reviews) (Shea et al., 2017), the included
SRs and meta-analyses should have conducted an adequate search of
at least two databases, assessed the risk of bias from individual studies
being included in the reviews, used appropriate methods of meta-
analysis, considered the risk of bias when interpreting the results of
the reviews, and if possible assess the presence and likely impact of
publication bias.
Participants had to be diagnosed as having a malignant tumor
according to their pathology and there were no restrictions on age,
gender, types of cancer, stages, complications, or previous treatment.
Types of interventions were defined as those with at least one arm
with one of the herbal injections in the national essential health
insurance program as either anti-cancer or adjuvant treatment for
cancer (ZC01 and ZC02 category, 2019 version) including those
currently in the access negotiation list during the agreement period
(National Health Insurance Agency, 2019). There were no
limitations on dosage, duration, and any combined therapy
should be standard therapy following the NCCN (National
Comprehensive Cancer Network) guideline without other TCM
interventions. The control group could be standard anti-cancer
treatment, placebo, or no treatment without other TCM
therapies. Primary outcomes included survival, tumor response,
or quality of life; secondary outcomes included cancer-related
symptoms, side-effects of chemo/radiotherapy or targeting
therapy, and immune function. No limitations were imposed on
study setting, language, or publication type. The articles with only
one author except for dissertation and conference abstracts without
details were excluded.
Search Strategy
We searched PubMed, EMBASE, Web of Science, and four major
Chinese electronic databases, China National Knowledge
Infrastructure (CNKI), Chinese Scientific Journals Database
(VIP), Chinese BioMedical Literature Database (SinoMed), and
Wanfang Database, from their inception to Dec 2nd, 2020. Ten
herbal injections - Compound Kushen, Shenqi Fuzheng, Aidi,
Kangai, Kanglaite, Xiaoaiping, Cinobufacin, Brucea javanica oil
emulsion, Polyporus polysaccharide injection and Astragalus
polysaccharide for injection - were searched independently.
Taking Aidi injection as an example, the following search
strategy was applied in PubMed:
#1 (Neoplasm) OR (Carcinoma) [MeSH Terms]
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1988 Extracts from Sophora
flavescens Aiton (Kushen),
Smilax glabra Roxb. (Baituling)
Actions: Clearing heat and
draining dampness,
cooling the blood and
resolving toxin, dissipating
binds and relieving pain;
Indications: Cancer pain
and bleeding
Intramuscular injection, 2∼4 ml
once, 2 times a day; or
intravenous drip, 20 ml once,
diluted with 200 ml sodium
chloride injection and applied,
once a day, children should
reduce it, the total amount of
systemic medicine 200 ml is a
course of treatment, generally it
can be used continuously for 2 to
3 courses; or as directed by a
doctor
Limited to be used for
middle and advanced










Action: Boosting qi and





dizziness caused by lung-
spleen-qi deficiency;
adjuvant treatment for lung
cancer and gastric cancer
with the above symptoms
Intravenous drip. 250 ml each
time (i.e., 1 bottle), once a day,
treatment for 21 days; combined
with chemotherapy, start to use
3 days before chemotherapy,
and the course of treatment can
end simultaneously with
chemotherapy





cancer and gastric cancer
together with evidence of
blood indicators and low
immune function








Panax ginseng C. A. Mey.
(Renshen), Mylabris phalerata
(Pallas) (Banmao)










50∼100 ml once, add 0.9%
sodium chloride injection or 5%∼
10% glucose injection
400∼450 ml, once a day; when
combined with radiotherapy and
chemotherapy, the course of
treatment is synchronized with
radiotherapy and chemotherapy;
use before and after surgery
10 days of this product is a
course of treatment; 10 days of
interventional treatment is a
course of treatment; 15 days of
single use is a cycle, with an
interval of 3 days, and 2 cycles
are a course of treatment; for
patients with advanced cachexia,
30 days of continuous use is a
course of treatment, or
depending on the condition
Limited to be used for
middle and advanced








ginseng C. A. Mey. (Renshen),
Ammothamnine













Slow intravenous injection or drip;
1–2 times a day, 40–60 ml a day,
diluted with 5% glucose or 0.9%
saline 250–500 ml before use.
30 days is a course of treatment
or as prescribed by doctor






(Continued on following page)
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1997 Oil fromCoix lacryma-jobi L. for
injection (Oil from Yiyiren)
Actions: Boosting qi and
nourishing yin, eliminating
mass and dissipating binds
Indications: Primary non-
small cell lung cancer and
primary liver cancer with qi-
yin deficiency pattern or
spleen deficiency and
dampness encumbrance






patients the medium and
advanced tumors
Slowly inject 200 ml
intravenously, once a day, for
21 days as a course of treatment,
and the next course of treatment
can be performed after an interval
of 3–5 days. When combined
with radiotherapy and
chemotherapy, the dose can be
reduced. For the first use, the drip
rate should be slow; the drip rate
should be 20 drops/min in the
first 10 min, it can continue to
increase after 20 min, and it can
be controlled at 40–60 drops/min
after 30 min
Limited to be used for
middle and advanced lung





2002 Marsdenia tenacissima (Roxb.)
Moon (Tongguanteng)
Actions: Clearing heat and
removing toxin, resolving
phlegm and softening
hardness; Indications: It is
used for esophageal
cancer, gastric cancer,
lung cancer, liver cancer,




Intramuscular injection: 2∼4 ml
once, 1∼2 times a day; or as
directed by a doctor. Intravenous
drip: Dilute with 5% or 10%
glucose injection and instill
infusion, 20∼100 ml once, once a
day; or follow the doctor’s advice
Limited to be used for
middle and advanced








tumors, chronic hepatitis B
and other diseases
Intramuscular injection, 2∼4 ml
once (2/5∼4/5), 2 times a day;
intravenous drip, once a day,
10∼20 ml (2∼4) once, injected
with 5% glucose Dilute 500 ml of
the solution and instill it slowly,
take the medicine for 7 days, rest
for 1 to 2 days, four weeks as a
course of treatment, or follow the
doctor’s advice
Limited to be used for





1994 Oil emulsion from Brucea






Intravenous drip, 10∼30 ml once
(1∼3 tubes at a time), once a day
(this product must be added with
250 ml of sterile normal saline,
use immediately after dilution)
Limited to be used for
middle and advanced





1999 Polyporus polysaccharide Indications: It can regulate
the immune function of the
body and has a certain




can enhance the efficacy
and reduce toxic side
effects
Intramuscular injection. 2∼4 ml
once, once a day, the children
should reduce it or follow the
doctor’s advice
Limited to be used for




(Continued on following page)
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#2 (Cancer*) OR (Tumor*) OR (Tumour*) OR (Malignant*)
[Title/Abstract]
#3 #1 OR #2
#4 (Aidi injection) [Title/Abstract]
#5 (random*) [Text Word]
#6 (meta) OR (systematic review) OR (review) [Title/Abstract]
#7 #5 OR #6
#8 #3 AND #4 AND #7
#9 (mice) or (mouse) or (rat) or (rabbit) [Title]
#10 #8 NOT #9
Study Selection and Data Extraction
The authors (SJZ and CS) screened the titles and abstracts of all
retrieved references after removing duplicates, and the full-text
was retrieved for further screening. MY checked all the eligible
studies and any disagreements were solved by discussion with SJZ
and CS. The data extraction was conducted by RZ, MF, YNG, LY,
ZYR, CS, SJZ, MY, and RXZ and validated by SJZ and MY. The
extracted information recorded was authors, publication year,
title, funding, randomization methods, single/multiple centers,
blinding, sample size, cancer type and stage, the TCM syndrome
classification, the controls, the administration, dosage, duration
of herbal injection, and the outcomes.
Data Synthesis
The basic information on the ten injections was summarized
according to the drug indications and the national essential health
insurance program list (2019 version) (National Health Insurance
Agency, 2019). The quantitative description and figures were
conducted with Microsoft Excel 2016 and RStudio statistical
software (RStudio; Boston, Massachusetts, United States).
RESULTS
The Basic Information of Ten Herbal
Injections in Cancer Care
The basic information of ten herbal injections involved in the
national essential health insurance program is listed in Table 1,
Supplementary Table S1. According to the classification of the
health insurance catalog, six injections were defined as ZC01 anti-
cancer drugs, and four were ZC02 adjuvant drugs for cancer. Four
injections contained more than one herbal composition, while six
injections contained a single compound or ingredients extracted
from a single herb as the main component. The health insurance has
made the following restrictions on the payment scope of each
injection. All injections were restricted to be used in secondary
and tertiary hospitals, except for two injections, Cinobufacin and
Polyporus polysaccharide.
The Selection of RCTs, Systematic Reviews
and Meta-analyses
The flow diagram of the literature selection is shown in Figure 1.
A total of 10,723 records were identified from the initial search
through seven databases. After removal of duplicates and
exclusion of references by reading titles and abstracts,
3134 full-text articles were screened and 2720 references were
excluded with reasons (seen in the flow chart). Finally, 414 studies
composed of 366 RCTs and 48 SRs and meta-analyses were
included in this evidence mapping.
The numbers of included studies of the ten herbal injections
are shown in Table 2. The top three injections in the included
RCTs were Compound Kushen (78, 21.3%), Shenqi Fuzheng
(76, 20.8%), and Aidi injection (63, 17.2%), and the top three
injections in the SRs were Kanglaite (10, 20.8%), Compound
Kushen (9, 18.8%), and Shenqi Fuzheng injection (8, 16.7%). No
eligible evidence was identified for Polyporus polysaccharide
injection. The remaining analysis only includes nine injections.
Bibliometric Information and
Characteristics of Included RCTs
In Table 3, the increasing overall trend in the number of studies is
demonstrated. Before 2009, trials were conducted sporadically.
The number increased rapidly after 2009 before plateauing from
2015, with about 40 to 60 newly published trials each year.









for injection (ZC02 adjuvant
treatment for cancer) (in





It can be used to treat
cancer patient with
leukopenia, impaired
immunity and low level of




sweating, short of breath,
and poor appetite due to qi
deficiency
Intravenous drip, use a syringe to
draw 10 ml saline into the vial,
shake immediately until the
medicine is completely dissolved,
then add it to 500 ml 0.9%
sodium chloride injection or
5–10% glucose injection, drip.
The time is not less than 2.5 h
250 mg once, once a day. The
course of treatment is 21 days for
patients with
immunocompromised function
and 7 days for other treatment
courses
Limited to be used in
secondary and tertiary
hospitals. A single
hospitalization can be paid
for up to 14 days
Note: ZC, the drug classification code, Z for Chinese patent herbal drugs and C for cancer medication. Approved year refers to the earliest time to market according to the approved
number for each injection.
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Geographical distribution of RCTs of nine herbal injections for
which there was eligible evidence was uneven according to
Figure 2. Published studies were located in 27 different
provinces and municipalities. The largest number of RCTs
were from Henan province (n  39), while no eligible
published RCTs were found in Jilin Province, Ningxia Hui
Autonomous Region, Tibet Autonomous Region, and Yunnan
Province. In Zhejiang Province, there were 14 studies on Shenqi
Fuzheng injection, the largest number of studies for one injection
in a single province.
The included RCTs involved a total of 31,233 cancer
participants, and the sample sizes of individual studies mostly
ranged from 51–100 (265, 72.4%) (Table 4). The included studies
involved 15 types of cancers and multiple cancer types, although
lung cancer was the most frequently studied type of cancer (118,
32.2%). Only 26 studies mentioned TCM syndrome, accounting
FIGURE 1 | Flow Diagram of the selection of RCTs, systematic reviews, and meta-analyses.
TABLE 2 | Number of included studies on ten Chinese herbal injections used in cancer care.
Name of the
Chinese herbal injections
No. of RCTs (%) No.
of SRs/meta-analyses (%)
Compound Kushen injection 78 (21.3) 9 (18.8)
Shenqi fuzheng injection 76 (20.8) 8 (16.7)
Aidi injection 63 (17.2) 5 (10.4)
Kangai injection 45 (11.7) 4 (8.3)
Kanglaite injection 36 (9.8) 10 (20.8)
Xiaoaiping injection 25 (6.8) 2 (4.2)
Cinobufacin injection 25 (6.8) 5 (10.4)
Brucea javanica oil emulsion injection 13 (3.6) 5 (10.4)
Polyporus polysaccharide injection 0 (0) 0 (0)
Astragalus polysaccharide for injection 5 (1.37) 0 (0)
Total 366 (100) 48 (100)
Note: RCTs, Randomized controlled trials; SRs, systematic reviews and meta-analyses.
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for 7.1%. Of the RCTs, 97.0% used injections with
conventional treatment as combined therapy. With regard
to the course of treatment of herbal injection, the injections
and standard therapy were implemented simultaneously in 297
studies. Among them, the injections started and ended at the
same time as the conventional therapy for each course in 157
studies (42.9%), and the other 140 studies (38.3%) had the
injections end early before the end of conventional treatment.
For the controls, the included RCTs mainly involved 13 types
of controls, among which palliative chemotherapy was used
most commonly (46.4%). As for the methodological
characteristics of the included RCTs, 341 RCTs (93.2%)
were single-center trials, and blinding was implemented
only in four trials (1.1%). A total of 92 RCTs reported
funding sources, of which 82 received government funding
(22.4%), seven university/hospital funding (1.9%), and three
received other support.
Of 366 studies, 336 RCTs studied the use of an injection to
treat a certain type of cancer and involved 15 different kinds of
cancer, while the remaining 30 RCTs studied the use of a specific
injection for multiple cancers (Figure 3). Lung cancer was the
most studied type of cancer, involving 118 RCTs on nine types of
injection, followed by colorectal cancer (39 studies) and stomach
cancer (39 studies), which both covered eight herbal injections. In
addition, Compound Kushen injection was tested on a wide range
of types of cancers (12 types).
TABLE 3 | The numbers of RCTs on ten herbal injections used in cancer care.
Name of the Chinese
herbal injections
2003 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
Compound Kushen injection 0 1 0 1 0 3 5 3 5 3 10 10 7 10 13 7
Shenqi Fuzheng injection 0 1 4 2 1 1 0 2 5 8 8 4 9 14 11 6
Aidi injection 0 1 0 0 4 2 1 2 1 7 8 11 8 8 5 5
Kangai injection 0 0 0 2 2 1 2 1 2 7 1 4 8 10 3 2
Kanglaite injection 1 1 0 0 0 0 2 1 2 0 6 3 3 9 7 1
Xiaoaiping injection 0 0 0 0 0 0 0 1 1 1 5 3 4 2 6 2
Cinobufacin injection 0 0 0 0 1 0 1 1 1 5 3 2 4 4 2 1
Brucea javanica oil emulsion injection 0 0 0 0 1 0 1 0 0 0 2 1 1 3 3 1
Astragalus polysaccharides for
injection
0 0 0 0 1 0 0 0 0 1 0 1 1 0 0 1
Total 1 4 4 5 10 7 12 11 17 32 43 39 45 60 50 26
FIGURE 2 | The geographical distribution of the primary investigators of RCTs on herbal injections for cancer care.
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Clinical Characteristics of the Included
Systematic Reviews and Meta-analyses
As shown in Table 5, the included 48 SRs involved a total of
65,884 participants, of which the sample size per review ranged
from 61 to 3433, mostly distributed in ≤1000 (23 SRs, 47.9%).
Seven types of cancer and multiple cancer syndromes were
evaluated in the SRs while lung cancer (20 SRs, 41.7%), liver
cancer (6 SRs, 12.5%), stomach cancer (5 SRs, 10.4%), and
colorectal cancer (5 SRs, 10.4%) were the most reviewed
cancers. It is worth mentioning that the injections were only
used as an add-on treatment in all of the 48 SRs. In addition, there
were six kinds of controls mentioned in the SRs while 35 SRs
(72.9%) included chemotherapy as the comparator.
Outcomes and Effects of the Herbal
Injections
The metrics of clinical outcomes and cancer types is shown in
Figure 4. The consistent beneficial effect (at least two trials
showed beneficial effect with no significant or harmful effects)
according to the reported RCTs are shown in dark green, and the
numbers of RCTs for each outcome are written in the cells. The
outcomes of included SRs are presented in Supplementary
Table S2.
Compound Kushen Injection
In the 78 RCTs for Compound Kushen injection, 11 cancer types
were included, with more than two trials for each type, and it was
commonly used for lung cancer (18, 23.1%), gastric cancer (10,
12.8%), colorectal cancer (7, 9.0%), and nasopharyngeal cancer
(7, 9.0%). Compared with conventional therapy alone, the
combined treatment with Compound Kushen injection showed
consistent beneficial effects on objective response rate (ORR) for
colorectal cancer (3 RCTs) and gastric cancer (2 RCTs), or a
disease control rate (DCR) for breast cancer (2 RCTs), and
pancreatic cancer (2 RCTs). It is worth mentioning that
adding in Compound Kushen injection showed consistent
effect on pneumonitis caused by radiation treatment in lung
cancer patients (4 RCTs) while all other injections had
insufficient consistent benefit on radiation pneumonitis. The
myelosuppression and immune function were also shown to
be improved in several cancer types based on 2-6 RCTs
(Figure 4).
In the nine SRs concerning Compound Kushen injection,
three SRs were for advanced non-small cell lung cancer
(NSCLC) patients. Compared with cisplatin-based
chemotherapy alone, Compound Kushen injection showed
beneficial effects for advanced NSCLC patients on ORR, KPS
scores, leukopenia in 3 SRs, one-year survival rate, DCR, cancer
pain relief, nausea and vomiting, diarrhea, alopecia, mucositis,
thrombocytopenia, and anemia in one SR (Supplementary
Table S2).
Shenqi Fuzheng Injection
In the 76 RCTs involving Shenqi Fuzheng injection, only one trial
tested Shenqi Fuzheng injection for immune function in lung
cancer patients during perioperative period compared with
normal saline, while other trials tested the add-on effect of
Shenqi Fuzheng injection. In terms of cancer types, 27 (35.5%)
of the trials examined Shenqi Fuzheng injection in lung cancer
patients, followed by breast cancer (12, 15.8%) and gastric cancer
(10, 13.2%). Among the survival and tumor responses, only ORR
for colorectal cancer showed consistent beneficial effect (3 RCTs).
Improved quality of life was found in breast cancer (2 RCTs),
gastric cancer (4 RCTs), and colorectal cancer (4 RCTs), and relief
of cancer fatigue was found in both lung (5 RCTs) and gastric
cancer patients (2 RCTs) with consistency. Add-on therapy with
Shenqi Fuzheng injection showed obvious consistent effect in
immune function in 3-5 trials (Figure 4).
In the eight SRs concerning Shenqi Fuzheng injection, three
SRs were for advanced NSCLC patients. Compared with cisplatin
based chemotherapy alone, Shenqi Fuzheng injection combined
with NP (navelbine and cisplatin), GP (gemcitabine and
cisplatin), and TP (paclitaxel and cisplatin) regimen showed
beneficial effects on ORR (2 SRs), KPS scores (3 SRs), cancer
fatigue (1 SR), cancer fever (2 SRs), leukopenia (3 SRs),
thrombocytopenia (3 SRs), anemia (2 SRs), and immune
function assessed by CD4, CD4/CD8, and NK cells level (2
SRs). In terms of breast cancer (2 SRs), compared with
chemotherapy alone, add-on with Shenqi Fuzheng injection
showed beneficial effects on ORR, KPS scores, alopecia, liver
and kidney function, leukopenia, thrombocytopenia, CD4, CD4/
CD8, and abnormal changes in electrocardiogram in two SRs, and
reducing cancer fatigue, nausea and vomiting, CD3, and NK cells
level in one SR (Supplementary Table S2).
Aidi Injection
Twenty-five out of 63 RCTs tested the effects of Aidi injection for
lung cancer. Compared with chemo or targeting therapy alone,
add-on with Aidi injection showed consistent effects on three-
year survival rate (2 RCTs), progression free survival (2 RCTs),
KPS scores (12 RCTs), and immune function assessed by CD4
and CD4/CD8 (10 RCTs) in lung cancer patients (Figure 4). The
add-on with Aidi injection showed beneficial effects on ORR (2
SRs), DCR (1 SR), KPS scores improvement (2 SRs), neutropenia
(1 SR), leukopenia (1 SR), thrombocytopenia (2 SRs), nausea and
vomiting (1 SR), and liver function (1 SR) compared to
chemotherapy alone in advanced NSCLC patients
(Supplementary Table S2).
Compared with chemotherapy alone, add-on with Aidi
injection showed significant effects on ORR (1 SR), DCR (1
SR), KPS scores (2 SRs), nausea and vomiting (1 SR),
peripheral neurotoxicity (1 SR), diarrhea (1 SR), immune
function (1 SR) assessed by CD3, CD4, CD4/CD8, and NK
cells level, and leukopenia (2 SRs) in colorectal cancer patients.
In one SR on liver cancer, it showed beneficial effects of add-on
with Aidi injection on ORR, KPS scores, survival rate, and
immune function assessed by CD3 and CD4 compared to
transarterial chemoembolization (TACE) treatment alone.
Compared with conventional therapy alone, the add-on
with Aidi injection showed consistent benefits on ORR in
liver cancer patients (6 RCTs), gastric cancer (3 RCTs),
multiple myeloma (3 RCTs), and ovarian cancer (2 RCTs).
The improvement of KPS scores were also observed in
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TABLE 4 | The clinical and methodological characteristics reported in the included RCTs of Chinese herbal injections for cancer care.
Items Details N (%)
Study setting Single-center study 341 (93.2)
Multicenter study 17 (4.6)
Not reported 8 (2.2)




Populations Lung cancer 118 (32.2)
Colorectal cancer 39 (10.7)
Stomach cancer 39 (10.7)
Liver cancer 32 (8.7)
Breast cancer 28 (7.7)
Hematological malignancy 19 (5.2)
Esophagus cancer 14 (3.8)
Cervical cancer 11 (3.0)
Nasopharyngeal cancer 10 (2.7)
Ovarian cancer 8 (2.2)
Pancreatic cancer 8 (2.2)
Prostate cancer 4 (1.1)
Bladder cancer 4 (1.1)
Renal cancer 1 (0.3)
Laryngeal cancer 1 (0.3)
Multiple cancer 30 (8.2)
TCM syndrome Reported 26 (7.1)
Not reported 340 (92.9)
Interventions Injection used as add-on treatment 355 (97.0)
Injection only 11 (3.0)
Time of administration of herbal injections Start and end at the same time as the standard therapy 157 (42.9)
Start at the same time as the standard therapy, but end earlier 140 (38.3)
Start before the standard therapy, but end at the same time as standard therapy 19 (5.2)
Start at the same time as the standard therapy, but end later 16 (4.4)
Start before the standard therapy, and end before the standard therapy 7 (1.9)
Start after the standard therapy 3 (0.8)
Start before the standard therapy and end earlier 2 (0.5)
Used alone 5 (1.4)
Othersa 17 (4.6)
Administration of herbal injections i.v.gtt 335 (91.5)
i.m 4 (1.1)
i.p 8 (2.2)
Thoracic perfusion 5 (1.4)
Arterial infusion 2 (0.5)
p.r 2 (0.5)
Multiple administrations 3 (0.8)
Not reported 7 (1.9)
Controls Palliative chemotherapy 170 (46.4)
Adjuvant chemotherapy 28 (7.7)
Chemo/radiotherapy 24 (6.6)
Radiotherapy 21 (5.7)
Curative chemotherapy (tumors of the blood, lymphatic and reproductive system) 19 (5.2)
Supportive/symptomatic treatment 16 (4.4)
Interventional therapya 14 (3.8)
Chemotherapy (Unable to identify the type) 11 (3.0)
Perfusion therapy (chemotherapy infused into the chest or abdomen) 11 (3.0)
Neoadjuvant chemotherapy 9 (2.5)
Targeted therapy 8 (2.2)
Placebo 2 (0.5)
Placebo with XELOX chemotherapy 1 (0.3)
Multiple controls 1 (0.3)
Othersa 31 (8.5)
Random sequence generation Random number tables 339 (92.6)
Draw lots 17 (4.6)
Computer-generated random sequences 4 (1.1)
Toss a coin 3 (0.8)
Random envelopes 3 (0.8)
(Continued on following page)
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colorectal cancer (4 RCTs), gastric cancer (2 RCTs), and
ovarian cancer (2 RCTs) (Figure 4).
Kangai Injection
Only one RCT compared Kangai injection with placebo for
advanced liver cancer; others tested combined effects of
Kangai injection and conventional therapy. Twelve studies
were focused on lung cancer. Compared with chemotherapy
alone in 10 RCTs, the add-on with Kangai injection showed
significant effects on DCR (3 RCTs), quality of life assessed by SF-
36 (2 RCTs), cancer fatigue (3 RCTs), tumor marker (2 RCTs),
and leukopenia (3 RCTs) in lung cancer patients. In liver cancer
trials, the add-on with Kangai injection showed effects on KPS
scores (5 RCTs) and improvement in liver function (7 RCTs)
compared with conventional therapy. In two SRs for liver cancer,
the combination of Kangai injection and TACE showed
improvement on KPS scores, cancer pain, leukopenia, anemia,
and liver function (Supplementary Table S2).
Other significant outcomes demonstrated ORR, KPS scores
improvement, neurotoxicity, and leukopenia in colorectal (1 SR)
and gastric cancer patients (1 SR), KPS scores improvement in
colorectal cancer patients (4 RCTs), and relieving nausea and
vomiting in gastric cancer patients (4 RCTs) (Figure 4).
Kanglaite Injection
Seventeen of the 36 included RCTs tested Kanglaite injection for
lung cancer. Compared with palliative chemotherapy alone, the
add-on with Kanglaite improved quality of life assessed by KPS
scores (6 RCTs) and EORTC-QLQ-C30 (5 RCTs), and the
immune function assessed by CD3 (7 RCTs), CD4 (8 RCTs),
and CD4/CD8 (6 RCTs). Compared with GP chemotherapy
alone, the add-on with Kanglaite reduced cancer pain in
advanced NSCLC patients (2 RCTs) (Figure 4). Eight out of
10 included SRs tested Kanglaite for lung cancer. Compared with
chemotherapy alone, Kanglaite combined with chemotherapy
showed significant effects on one-year survival rate (2 SRs),
ORR (6 SRs), DCR (4 SRs), improved KPS scores (6 SRs),
weight improvement (1 SR), nausea and vomiting (4 SRs),
leukopenia (4 SRs), thrombopenia (3 SRs), anemia (1 SR),
improvement on CD3 level (2 SRs), CD4 level (3 SRs), CD4/
CD8 (2 SRs), and NK cells level (1 SR) in lung cancer patients.
Compared with gefitinib alone, the add-on with Kanglaite
improved KPS scores in lung cancer patients (2 SRs)
(Supplementary Table S2).
In addition, combining Kanglaite with conventional treatment
also showed beneficial effects on ORR and reducing cancer fever
in liver cancer patients (2 RCTs), reducing nausea and vomiting
TABLE 4 | (Continued) The clinical and methodological characteristics reported in the included RCTs of Chinese herbal injections for cancer care.
Items Details N (%)
Blinding Blinding 4 (1.1)
No blinding 362 (98.9)
Funding source Government 82 (22.4)
University/hospital 7 (1.9)
Multiple funding 1 (0.3)
Charity fund 1 (0.3)
Medical association 1 (0.3)
Not reported 274 (74.9)
Notes: i.v.gtt, intravenous drip; i.m., intramuscular injection; i.p., intraperitoneal injection; p.r., rectal administration.
Interventional therapy: including transarterial chemoembolization (TACE) and radiofrequency ablation.
aOther timing of administration of Chinese herbal injection including used before control, or started days before the surgery and stopped days after the surgery, or used for 21 days
continuously and stopped for 7 days without relation to the control, etc.Other controls including Interleukin infused into the abdomen, analgesia therapy, adjuvant chemotherapy combined
with palliative chemotherapy, antiviral therapy, perfusion therapy into bladder, etc.
FIGURE 3 | Evidence mapping of the distribution of nine herbal injections by cancer type.
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(2 RCTs), leukopenia (1 SR), improving ORR (1 SR) in gastric
cancer patients, and improving KPS scores (2 RCTs) and
leukopenia in cervical cancer patients (2 RCTs) (Figure 4).
Xiaoaiping Injection
Nine out of 25 RCTs tested the add-on effect of Xiaoaiping
injection for lung cancer. Compared to palliative platinum-based
chemotherapy alone, the combined treatment with Xiaoaiping for
14 to 21 days in one chemotherapy cycle for 2-4 cycles showed
beneficial effects on KPS scores (6 RCTs), improvement of white
blood cell reduction (6 RCTs), and CD4 and CD4/CD8 level (3
RCTs) in IIIB-IV advanced lung cancer patients. The evidence
mapping also showed that compared with chemotherapy alone,
palliative chemotherapy with oxaliplatin and Xiaoaiping
(intravenous infusion or enema) improved KPS scores for
colorectal cancer (2 RCTs). No consistent beneficial effect was
observed in the included RCTs in breast and gastric cancer
patients (Figure 4). Compared to TACE alone, Xiaoaiping
plus TACE showed significant effects on ORR and KPS scores
in liver cancer patients (1 SR). Compared with chemotherapy
alone, Xiaoaiping plus chemotherapy showed significant effects
on improving appetite, dysphagia, cancer pain, and KPS scores in
esophageal cancer patients (1 SR) (Supplementary Table S2).
Cinobufacin Injection
Seven out of 25 RCTs of Cinobufacin injection were for liver
cancer. Compared with radiotherapy or TACE therapy alone, the
add-on with intravenous or artery perfusion of Cinobufacin
showed consistent effects on one-year survival rate (2 RCTs
and 1 SR), two-year survival rate (1 SR), KPS scores (1 RCT
and 1 SR), ORR (1 RCT and 1 SR), DCR (1 RCT), and tumor
marker (3 RCTs) in liver cancer. Compared with supportive care
alone, the combination with intravenous or intraperitoneal
perfusion of Cinobufacin showed a beneficial effect on
improved KPS scores in two trials for liver cancer. In terms of
lung cancer, the add-on with Cinobufacin to chemotherapy
showed significant effects on one-year survival rate (1 SR),
two-year survival rate (2 SRs), improved KPS scores (2 SRs),
ORR (2 SRs), relief for cancer pain (2 SRs), nausea and vomiting
(1 SR), leukopenia reduction (1 SR), and thrombocytopenia
reduction (2 SRs), but increased phlebitis occurrence, which
was the only harmful outcome identified in one SR
(Supplementary Table S2).
In addition, the add-on with Cinobufacin to chemo/
radiotherapy also showed beneficial effect on ORR for
colorectal cancer (3 RCTs) (Figure 4). In esophageal cancer
trials, add-on with Cinobufacin showed significant effect on
one- and two-year survival rate compared with radiotherapy
(1 SR). Cinobufacin combined with chemotherapy was also
associated with better effects than chemotherapy alone in
improving ORR and KPS scores in gastric cancer (1 SR).
Brucea javanica Oil Emulsion Injection
The evidence mapping showed beneficial effects for lung cancer
and gastric cancer in RCTs combined with Brucea javanica oil
emulsion injection. Compared with palliative platinum-based
chemotherapy or gefitinib alone, add-on with Brucea javanica
oil emulsion showed beneficial effects on KPS score and immune
function including CD3, CD4, and CD4/CD8 level in lung cancer
patients (3 RCTs). Compared with palliative chemotherapy with
oxaliplatin or paclitaxel alone, adding Brucea javanica oil
emulsion showed beneficial effects on ORR (3 RCTs) and
DCR (2 RCTs) in gastric cancer patients (Figure 4).
Compared with chemotherapy alone, Brucea javanica oil
emulsion showed significant effects on ORR, improved quality
of life, and reduced leukopenia events in lung cancer (2 SRs), and
TABLE 5 | The clinical characteristics of the included systematic reviews and meta-analyses of Chinese herbal injections for cancer care.
Items Details N (%)




Populations Lung cancer 20 (41.7)
Liver cancer 6 (12.5)
Colorectal cancer 5 (10.4)
Stomach cancer 5 (10.4)
Breast cancer 3 (6.3)
Esophagus cancer 3 (6.3)
Hematological malignancy 1 (2.1)
Multiple cancer 5 (10.4)
Interventions Injection used as add-on treatment 48 (100.0)
Administration of herbal injections Intravenous drip 5 (10.4)
Multiple routes of administrations 2 (4.2)
Not reported 41 (85.4)
Controls Chemotherapy 35 (72.9)
Transarterial chemoembolization (TACE) 6 (12.5)
Targeting therapy 2 (4.2)
Others 5 (10.4)
Other controls included radiotherapy, radiotherapy alone or chemoradiotherapy, radiotherapy and conventional therapy for cancer pain, chemo or radiotherapy, and chemotherapy or
chemotherapy with conventional therapy.
Frontiers in Pharmacology | www.frontiersin.org May 2021 | Volume 12 | Article 66636811
Yang et al. Clinical Application of Herbal Injections
FIGURE 4 | Evidence mapping of the reported clinical outcomes by cancer types (Two or more RCTs for a single cancer type were shown in Figure 4. Dark green:
at least two trials showed consistent beneficial effect for all measurements on summarized outcome with no significant or harmful effects; Light green: some of the
reported outcomes showed beneficial effect and some did not show significant effect; Yellow: a single study reported the outcome in spite of the direction of the effect.
Blue: all of the reported outcomes showed no significant effects; Red: any study showed harmful effects. The number in dark green cells presented the number of
RCTs. ORR, objective response rate; DCR, disease control rate; Quality of life includes KPS scores, ECOG scores and other scales for quality of life; Cancer related
symptoms include fatigue, cancer pain, cancer fever and decrease of weight; Side-effects of radiotherapy include radiation pneumonitis, radiation esophagitis and
radiation enteritis; Gastrointestinal side-effects of chemotherapy include nausea and vomiting, diarrhea, and constipation; myelosuppression includes leukopenia,
neutropenia, thrombocytopenia, anemia, and erythrocytopenia; Immune function includes CD3, CD4, CD4/CD8, and NK cell level.).
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advanced colorectal cancer (1 SR). One SR found that add-on
with Brucea javanica oil emulsion significantly improved one-
year and two-year survival rate and ORR compared to
radiotherapy alone in esophagus cancer (Supplementary
Table S2).
Astragalus Polysaccharide for Injection
Two RCTs using Astragalus polysaccharide for injections were
identified for the treatment of lung cancer. The combination of
Astragalus polysaccharide for injections and radiotherapy (1
RCT) or palliative chemotherapy (1 RCT) improved the
leukopenia and increased the level of CD3, CD4, and CD4/CD8.
DISCUSSION
Summary of Findings
This evidence mapping for Chinese herbal injection in cancer
care was based on 366 RCTs and 48 SRs and meta-analyses and
provided a broad overview on available evidence of herbal
injections and the effects on outcomes in different cancer
types. More than half of the RCTs were for Compound
Kushen, Shenqi Fuzheng, and Aidi injection, and nearly
one-third of the diseases in RCTs were lung cancer,
followed by colorectal cancer and gastric cancer. The
majority of the RCTs and all SRs examined the add-on
effect of herbal injections.
The outcome and effect metric showed generally similar
applications in herbal injections in cancer care. More
consistent benefits were observed in Compound Kushen,
Shenqi Fuzheng, Aidi, and Kangai injections for tumor
response, quality of life, myelosuppression, and immune
function improvement. The survival outcomes were only
reported consistently for Aidi and Cinobufacin injections
based on four individual RCTs. The most reported outcomes
of relieving side-effects of the standard therapy were nausea and
vomiting, white blood cells, CD4 levels, and CD4/CD8.
Differences From Previous Studies
The use of mapping to provide an evidence summary has been
used in the Chinese medicine field for Chinese herbs for
hypertension (Wei et al., 2019), Taiji (Solloway et al., 2016),
and massage (Miake-Lye et al., 2019), but there has been no
evidence mapping report on Chinese herbal injections. Most of
the articles published in English on Chinese herbal injections
were literature reviews (Wang et al., 2018), mainly introducing
the biological mechanisms or network meta-analyses (Zhang
et al., 2018), comparing different injections for a specific
clinical question in one cancer type, or animal studies (Zhu
et al., 2019) or in vitro study (Zheng et al., 2020).
Limitations
Several limitations existed in the study. Firstly, a complete
assessment of study quality for all included RCTs and SRs was
not manageable, therefore only key components were used as a
compromise. Secondly, we did not contact the authors of the
primary trials to understand the most unclear risk of bias in the
implementation of the trials. Some trials with low risk of bias may
not have been included due to incomplete reporting, so the
evidence mapping may not be sufficiently comprehensive to
reflect the whole quality of evidence in this field. Thirdly, the
study selection and data extraction were not done independently
by two persons, which may lead to a possible selection bias.
Implications for Future Research
Several implications could be raised for future research in Chinese
herbal injections for cancer care. Firstly, the evidence mapping
presented the evidence gap on overall and progress-free survival.
Though tumor response was also reported in some trials, it was
only an alternative outcome and could not fully represent clinical
benefit. Large-scale observational studies or RCTs with a well-
designed follow-up period are warranted (Xu et al., 2017).
Secondly, outcomes on quality of life showed the most
consistent beneficial effects among different cancer types.
However, most of them were evaluated by KPS scores, which
is not a comprehensive scale for quality of life as it reflected the
functional status (Terret et al., 2011). Research focusing on this
area with latest scales or patient-reported outcomes, for example,
the Patient-Reported Outcomes version of the Common
Terminology Criteria for Adverse Events (PRO-CTCAE),
would help doctors and patients know more advantages and
disadvantages of the injections on quality of life (Kluetz et al.,
2016). Thirdly, the trials seldom reported the syndrome
differentiation. Though there is still no consensus on whether
it is needed for all herbal injections, eight of ten included
injections used expressions in traditional Chinese medicine
theory for the description of indications, which suggested most
herbal injections in cancer care need syndrome differentiation.
The low percentage showed a severe lack of reporting and was a
limitation of the study design. Fourthly, in a majority of the
included trials, herbal injections were used combined with
chemotherapy drugs. Though some of the trials discussed the
effect of “increased efficiency and reduced toxicity”, it was not
clear enough. The knowledge gap of the herb-drug interaction
needs more attention and further clinical studies of
pharmacokinetics and pharmacodynamics in the combined use
of herbal injections and chemotherapy are extremely
warranted.(Yeung et al., 2018).
Implications for Clinical Practice and Policy
Making
The evidence mapping suggested the possible clinical status of the
included injections. Compound Kushen, Aidi, Kanglaite, and
Cinobufacins injections have anti-tumor effects and appear to
have beneficial survival outcomes. Shenqi Fuzheng and
Astragalus polysaccharide injections have adjuvant treatment
effects. Although there was a certain benefit to the objective
response rate of tumors, Kangai, Xiaoaiping, and Brucea javanica
oil emulsion injections need further trials to optimize the
characteristics to clarify the clinical indications due to the
limited survival outcome reported. As there is an obvious lack
of evidence, it is difficult to support the clinical indications for
Polyporus polysaccharide injections.
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For clinical practice, this evidence mapping presents a precise
and comprehensive summary of the clinical application of
Chinese herbal injections: Aidi for lung and liver cancer;
Cinobufacin for liver cancer; Compound Kushen and Brucea
javanica oil emulsion for gastrointestinal cancer, especially for
pancreatic cancer; Compound Kushen for radiation pneumonitis;
Xiaoaiping for quality of life in lung cancer; the adjuvant effect of
Shenqi Fuzheng for myelosuppression; Kangai for liver function;
and Kanglaite to support immune function. These results were
drawn from RCTs with consistent findings, showing very
promising effects. However, in clinical practice, the current
health insurance regulations and drug indications are currently
too broad to support a clinician’s choice of a specific treatment.
Given the promising findings in this evidence mapping, the use of
these injections could be wider if supported by further large well-
designed trials or real world studies.
The research on time and duration of herbal injections’
administration still needs more exploration. RCTs on the early
use of herbal injections before standard treatment began were
rare, at less than 10%. At the same time, the results showed that
herbal injections had advantages on the improvement of
myelosuppression and immune function, which were critical
indicators of whether to continue treatment before and during
chemotherapy. Due to drug indications and medical insurance
regulations, it is not possible to use herbal injections in advance to
achieve and maintain the above functions so as to help ensure the
successful completion of chemotherapy.
As Table 2 presented, over 40% of the included herbal
injections were used for the same period as standard
treatment, such as intravenous administration for 21 days.
Some of the drug indications were also used in consecutive
21–30 days of treatment. As far as we know, it was different
from the clinical reality as the patients asked to be discharged
from hospital when they finished the current cycle treatment and
were unable to receive the herbal injections in outpatient
departments or in primary care, as eight of ten injections
within the health insurance program were limited use in
secondary or tertiary hospitals. As a result, the gap between
drug indication, research evidence, and clinical practice needs
more consideration and clarification.
For policy making, some of the outcomes and effects of
injections in the anti-tumor category and adjuvant cancer
treatment category were very similar based on the included
evidence, but there would be differences in the medical
insurance payment according to the category. In addition,
health economics research based on high-quality evidence is
urgently needed to compare the clinical effects, side effects,
and comprehensive drug costs of different injections, so as to
provide more objective evaluation for decision-making.
CONCLUSION
Since the 21st century, high-level evidence including RCTs,
systematic reviews, and meta-analyses of Chinese medicine
injection in cancer care has gradually increased. The current
evidence mapping provided a visual overview of the beneficial
effects for herbal injections in cancer care. The clinical benefits and
evidence gaps offered useful information for different stakeholders
and for informing policy and clinical decision makers.
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